PC
Polar Capital Portfolio holdings
AUM
$13.5B
This Quarter Return
+0.63%
1 Year Return
+55.85%
3 Year Return
+125.38%
5 Year Return
+259.12%
10 Year Return
–
AUM
$10.9B
AUM Growth
+$10.9B
(-4.4%)
Cap. Flow
-$364M
Cap. Flow
% of AUM
-3.34%
Top 10 Holdings %
Top 10 Hldgs %
25.24%
Holding
324
New
42
Increased
91
Reduced
108
Closed
45
Top Buys
| 1 |
Apple
AAPL
|
$62.5M |
| 2 |
Intuitive Surgical
ISRG
|
$59.2M |
| 3 |
Edwards Lifesciences
EW
|
$57.8M |
| 4 |
AbbVie
ABBV
|
$56.2M |
| 5 |
Agilent Technologies
A
|
$54.9M |
Top Sells
| 1 |
Arista Networks
ANET
|
$58.9M |
| 2 |
MDSO
Medidata Solutions, Inc.
MDSO
|
$55.9M |
| 3 |
Pfizer
PFE
|
$51.6M |
| 4 |
Visa
V
|
$49.4M |
| 5 |
Autodesk
ADSK
|
$46.1M |
Sector Composition
| 1 | Technology | 28.86% |
| 2 | Financials | 24.44% |
| 3 | Healthcare | 16.93% |
| 4 | Communication Services | 9.5% |
| 5 | Consumer Discretionary | 6.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
226
KVH Industries
KVHI
$110M
| $2.7M | 0.02% |
253,695
| – | – |
|
227
Intel
INTC
$107B
| $2.52M | 0.02% |
48,984
-153,333
| -76% | -$7.9M |
|
228
Replimune Group
REPL
$422M
| $2.43M | 0.02% |
175,000
| – | – |
|
229
Ascendis Pharma
ASND
$11.8B
| $2.41M | 0.02% |
25,000
| – | – |
|
230
Fate Therapeutics
FATE
$120M
| $2.33M | 0.02% |
150,000
| – | – |
|
231
Cloudflare
NET
$72.7B
| $2.32M | 0.02% |
+125,000
| New | +$2.32M |
|
232
Bandwidth Inc
BAND
$452M
| $2.32M | 0.02% |
35,569
-25,382
| -42% | -$1.65M |
|
233
HDFC Bank
HDB
$182B
| $1.88M | 0.02% |
32,942
+16,263
| +98% | +$928K |
|
234
Crinetics Pharmaceuticals
CRNX
$2.92B
| $1.36M | 0.01% |
90,382
-9,618
| -10% | -$145K |
|
235
Zymeworks
ZYME
$1.12B
| $1.24M | 0.01% |
+50,000
| New | +$1.24M |
|
236
NetEase
NTES
$86.2B
| $1.03M | 0.01% |
3,858
+203
| +6% | +$54K |
|
|
VNET
237
VNET Group
VNET
$2.33B
| $742K | 0.01% |
97,436
+3,500
| +4% | +$26.7K |
|
|
JOBS
238
DELISTED
51job, Inc.
JOBS
| $705K | 0.01% |
9,525
-2,304
| -19% | -$171K |
|
239
Summit Therapeutics
SMMT
$17.6B
| $537K | ﹤0.01% |
300,000
-44,681
| -13% | -$80K |
|
|
VRNA
240
Verona Pharma
VRNA
$9.16B
| $457K | ﹤0.01% |
100,000
| – | – |
|
241
Mercado Libre
MELI
$125B
| $415K | ﹤0.01% |
753
+95
| +14% | +$52.4K |
|
242
Y-mAbs Therapeutics
YMAB
$388M
| $404K | ﹤0.01% |
+15,502
| New | +$404K |
|
|
FENG
243
Phoenix New Media
FENG
$28.7M
| $368K | ﹤0.01% |
143,875
+58,504
| +69% | +$150K |
|
|
NBIS
244
Nebius Group N.V. Class A Ordinary Shares
NBIS
$16.3B
| $268K | ﹤0.01% |
7,667
-1,286
| -14% | -$45K |
|
245
Esquire Financial Holdings
ESQ
$838M
| $256K | ﹤0.01% |
10,325
-2,464
| -19% | -$61.1K |
|
246
Goldman Sachs
GS
$226B
| $218K | ﹤0.01% |
+1,053
| New | +$218K |
|
247
iQIYI
IQ
$2.55B
| $212K | ﹤0.01% |
+13,166
| New | +$212K |
|
248
Adverum Biotechnologies
ADVM
$64.6M
| – | – |
-626,482
| Closed | -$7.45M |
|
249
Align Technology
ALGN
$10.3B
| – | – |
-17,946
| Closed | -$4.91M |
|
250
Avantor
AVTR
$9.18B
| – | – |
-2,264,049
| Closed | -$43.2M |
|